This technology is a set of lipopeptides with enhanced solubility that can be used as prophylactic therapies against SARS-CoV-2 and MERS viral infections.
Although vaccines have proven effective against SARS-CoV-2, emerging variants and declining vaccination rates necessitate new strategies to neutralize infection from evolving viral strains. Orthogonal methods to mitigate viral infections and dampen transmission would significantly benefit public health. Particularly, prophylactic treatments that generally inhibit SARS-CoV-2 viral fusion with host cells could provide a variant-agnostic approach for disease treatment that addresses ongoing public health challenges with this family of viruses.
This technology is a set of lipopeptides developed to inhibit the fusion of SARS-CoV-2 and MERS viruses with human host cells. They were designed in a structure-guided manner with charged residues at specific sites to enhance their solubility. This enhanced solubility in a physiological environment will improve their clinical utility for use as prophylactic treatments of SARS-CoV-2 and MERS viral infections.
This technology has been validated with human cell lines.
Patent Pending
IR CU25029
Licensing Contact: Kristin Neuman
